Eton Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ETON Eton Pharmaceuticals Inc
LXRX Lexicon Pharmaceuticals Inc
BVS Bioventus Inc
TDS-U Telephone and Data Systems Inc
ELEV Elevation Oncology Inc
FRZA Forza X1 Inc
SIEN Sientra Inc
PMGM Priveterra Acquisition Corp
NVFY Nova LifeStyle Inc
GGIFF Garibaldi Resources Corp
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Eton Pharmaceuticals, Inc. is a pharmaceutical company, which is developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. It has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. It also has three additional product candidates in late-stage development. The Company is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.

Price
Delayed
$3.87
Day's Change
-0.02 (-0.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.93
Day's Low
3.85
Volume
(Light)

Today's volume of 4,416 shares is on pace to be much lighter than ETON's 10-day average volume of 46,800 shares.

4,416

DraftKings Inc.: Please contact the Portnoy Law Firm to recover your losses; May 8, 2023 deadline

5:14 pm ET March 14, 2023 (Globe Newswire) Print
DraftKings Inc.: Please contact the Portnoy Law Firm to recover your losses; May 8, 2023 deadlineGlobeNewswireMarch 14, 2023

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, March 14, 2023 (GLOBE NEWSWIRE) -- â??The Portnoy Law Firm advises DraftKings Inc. ("Company" or "DraftKings") (NASDAQ: DKNG) non-fungible tokens ("NFTs") investors that a lawsuit filed on behalf of investors that purchased DraftKings (NASDAQ: DKNG) securities between August 11, 2021 and the present.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

During the Class Period, the Complaint claims that: (1) DraftKings did not file a registration statement for the NFTs, which were deemed securities; (2) DraftKings maintained control over the private marketplace, where class members' invested funds were held, artificially boosting the market and value of DraftKings' NFTs; and (3) investors sustained considerable losses.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.

Admitted CA and NY Bar

lesley@portnoylaw.com

310-692-8883

www.portnoylaw.com

Attorney Advertising



Primary Logo

comtex tracking

COMTEX_426604872/2010/2023-03-14T17:14:57

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.